Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
307.27B
Market cap307.27B
Price-Earnings ratio
35.92
Price-Earnings ratio35.92
Dividend yield
2.63%
Dividend yield2.63%
Average volume
9.19M
Average volume9.19M
High today
$124.93
High today$124.93
Low today
$124.40
Low today$124.40
Open price
$127.29
Open price$127.29
Volume
14.83K
Volume14.83K
52 Week high
$131.74
52 Week high$131.74
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

As of today, Merck(MRK) shares are valued at $124.52. The company's market cap stands at 307.27B, with a P/E ratio of 35.92 and a dividend yield of 2.63%.

On 2026-07-21, Merck(MRK) stock traded between a low of $124.40 and a high of $124.93. Shares are currently priced at $124.52, which is +0.1% above the low and -0.3% below the high.

Merck(MRK) shares are trading with a volume of 14.83K, against a daily average of 9.19M.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $131.74 at its peak.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $131.74 at its peak.

MRK News

Benzinga 16h
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio - Benzinga

...

Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio - Benzinga
Barron's 1d
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

Biotech and Pharma Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. In this article MRK BMY PFE AMGN JNJ The next standard cancer...

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
Simply Wall St 1d
Palantir Stock Price Still Misses Its Cash Flow Strength

With inflation and interest-rate expectations pulled in different directions by oil prices, geopolitics, and uneven growth data, a lot of stocks are being price...

Palantir Stock Price Still Misses Its Cash Flow Strength

Analyst ratings

66%

of 29 ratings
Buy
65.5%
Hold
27.6%
Sell
6.9%

More MRK News

Barron's 1d
What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

Biotech and Pharma What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment. In this article MRK BMY AZN SMMT ROP The next standard ca...

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
Simply Wall St 2d
Merck Stock And 2 Cash Flow Picks Trading Below Fair Value

With inflation trends, interest rates and energy prices all pulling markets in different directions, reliable cash generation has become a key focus for many in...

Merck Stock And 2 Cash Flow Picks Trading Below Fair Value
Simply Wall St 2d
Merck Stock Looks Cheap On Cash Flow While Earnings Look Fair

Merck stock has delivered a strong 92.2% return over the past 5 years, yet its current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic...

Merck Stock Looks Cheap On Cash Flow While Earnings Look Fair
Simply Wall St 3d
Merck Wins FDA Approval For First Once Daily Oral PCSK9 Drug

Merck (NYSE:MRK) has received FDA approval for Lipfendra, the first once daily oral PCSK9 inhibitor for lowering LDL cholesterol. Lipfendra offers an oral alte...

Merck Wins FDA Approval For First Once Daily Oral PCSK9 Drug
Investor's Business Daily 4d
Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.

Technology Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies. Licensing Personalis (PSNL) stock popped Friday on a rumor Merck (MRK) and at...

Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.
Seeking Alpha 4d
Personalis is said to have attracted takeover interest from Merck

Personalis (PSNL) shares added ~4% in the premarket on Friday following a report indicating that the company is exploring a potential sale after receiving takeo...

Personalis is said to have attracted takeover interest from Merck
TipRanks 4d
Personalis price target raised to $17 from $12 at Needham

Needham raised the firm’s price target on Personalis (PSNL) to $17 from $12 and keeps a Buy rating on the shares following a blog report that the company has re...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.